These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 582449)
1. Absorbed dose to ovaries and uterus during 131I-treatment of hyperthyroidism: comparison between in vivo TLD measurements and calculations. Philippon B; Briere J Health Phys; 1979 Jun; 36(6):727-9. PubMed ID: 582449 [No Abstract] [Full Text] [Related]
2. Absorbed dose to ovaries or uterus during a 131I-therapeutic of cancer or hyperthyroidism: comparison between in vivo measurements by TLD and calculations. Briere J; Philippon B Int J Appl Radiat Isot; 1979 Oct; 30(10):643-6. PubMed ID: 583466 [No Abstract] [Full Text] [Related]
3. Iodine-131 treatment of Graves' disease using modified early iodine-131 uptake measurements in therapy dose calculations. Hayes AA; Akre CM; Gorman CA J Nucl Med; 1990 Apr; 31(4):519-22. PubMed ID: 2324829 [TBL] [Abstract][Full Text] [Related]
4. Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. Robertson JS; Gorman CA J Nucl Med; 1976 Sep; 17(9):826-35. PubMed ID: 956897 [TBL] [Abstract][Full Text] [Related]
5. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I. Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745 [TBL] [Abstract][Full Text] [Related]
6. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. Nordyke RA; Gilbert FI J Nucl Med; 1991 Mar; 32(3):411-6. PubMed ID: 2005449 [TBL] [Abstract][Full Text] [Related]
8. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters. Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537 [TBL] [Abstract][Full Text] [Related]
9. [131I-therapy of Basedow's disease and nonimmunogenic hyperthyroidism]. Hoeschel M; Heinze HG Nuklearmedizin; 1984 Jun; 23(3):143-9. PubMed ID: 6548309 [TBL] [Abstract][Full Text] [Related]
10. Radioactive iodine in the treatment of Graves' disease. Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710 [TBL] [Abstract][Full Text] [Related]
11. A simplified method for treating Graves' disease with radioactive 131I. Masri MT; Menne M; Rooney BL; Caplan RH Wis Med J; 1995 Jan; 94(1):21-5. PubMed ID: 7871797 [TBL] [Abstract][Full Text] [Related]
12. A thermoluminescent method for the evaluation of the Meftah S; Kraiem T Radiat Environ Biophys; 2021 May; 60(2):289-298. PubMed ID: 33797646 [TBL] [Abstract][Full Text] [Related]
13. [Radioiodine treatment in Basedow's disease]. Rösler H Schweiz Med Wochenschr; 1976 Sep; 106(36):1215-8. PubMed ID: 1036630 [TBL] [Abstract][Full Text] [Related]
14. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease. Baczyk M; Junik R; Ziemnicka K; Sowiński J Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495 [TBL] [Abstract][Full Text] [Related]
15. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892 [TBL] [Abstract][Full Text] [Related]